Skip to main content
OpenTrials
Recruiting

NCT Number: NCT04985032

Accelerated Partial Breast Irradiation (APBI) Using Stereotactic Body Radiation Therapy (SBRT)

This is a multi-institutional, prospective, observational registry investigating the safety and efficacy of Accelerated Partial Breast Irradiation (APBI) using a Stereotactic Body Radiation Therapy (SBRT) delivery technique that incorporates real-time image guidance, noncoplanar fields, and respiratory tracking. The study will accrue 200 patients who will be treated to a dose of 30 Gy over the course of 5 fractions. These subjects will then have a follow up time of 5 years

Recruiting

Interested in participating?

Request Info

Key information

Age range

50 year–100 year

Sex eligibility

Female

Study type

Observational

Primary location

CyberKnife Center of South Florida in Stuart, Stuart, Florida, United States

Loading trial locations.

About this study

RADIATION TREATMENT GUIDELINES and DOSIMETRY Fiducial Placement Prior to enrollment, patients will undergo breast conservation surgery preferably with fiducial markers implanted at the time of surgery or under ultrasonic guidance25

Patients treated with gantry-based SBRT preferably will have fiducials placed at the time of surgery.

For patients being treated with CyberKnife SBRT, four gold markers will be placed intraoperatively or ultrasonically to define the superior, inferior, medial, and lateral boundaries of the lumpectomy cavity in accordance with the manufacturer's (Accuray) documentation. At least three fiducials will be required for target tracking purposes to allow for rotational changes.

Simulation Linear Accelerator SBRT For treatments on a gantry-based linear accelerator, patients will be positioned supine with the arms elevated. CT scans will be obtained with 1.25 mm thickness and will be acquired with free breathing as well as additional scans as needed for motion control or gating. 4DCT, MRI and PET imaging may be used to assist in determining motion estimation.

CyberKnife SBRT For treatment on a robotic system, a contrast enhanced CT simulation is to be performed with 1 mm slices with the patient's arms at her sides in the supine position. The scan is to be performed with end-inspiratory breath hold from the thyroid to below the lungs. Breast immobilization devices including a vacuum mattress and a bra system will be allowed however bolus should not be used. Fiducial tracking (Synchrony) is to be used for motion tracking.

DOSIMETRY Target and Organs at Risk (OAR) contours

The following structures are to be contoured in all patients:

Tumor cavity (GTV) as defined on CT including all fiducials implanted on CT images Clinical Target Volume (CTV) defined as the tumor cavity expanded by a uniform 15 mm margin. The CTV will not extend beyond the skin, breast or chestwall Planning Tumor Volume (PTV) for SBRT will be defined as the CTV plus 3 - 5 mm as needed at the treating physician's discretion. PTV will be limited to GTV plus 20 mm margin Skin is defined as <5 mm inside the external contour Chest wall includes the ribs and intercoastal musculature but does not include the pectoralis Heart contour begins below the level of where the pulmonary trunk branches into the left and right pulmonary arteries Lungs are to be contoured separately Spinal canal Breasts are to be contoured separately Dose Prescription The total prescribed dose to the PTV is 30 Gy delivered in 5 equal fractions of 6 Gy per day delivered on alternating days over 5 -10 total days. The prescribed dose must cover at least 95% of the PTV.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Women 50 years or older
  • Low to intermediate grade DCIS or invasive ductal carcinoma
  • Tumor size < 2 cm invasive ductal carcinoma and < 2.5 cm DCIS
  • Well defined lumpectomy cavity on CT
  • Clear surgical ink margins > 2mm for invasive cancer and > 3 mm for DCIS
  • Node negative
  • Unifocal lesion
  • ER and/or PR positive
  • HER-2 negative
  • BRCA negative
  • Lumpectomy cavity must be < 30% of whole breast volume

Exclusion criteria

  • Lobular histology
  • Angiolymphatic invasion
  • Multiple foci of disease
  • Lymphovascular invasion
  • Active lupus or sarcoid
  • Distant metastases
  • Non-epithelial malignancies
  • Synchronous contralateral breast cancer
  • Grade 2 or higher oncoplastic surgery
  • Ipsilateral pacemaker
  • Ipsilateral breast implant
  • Neoadjuvant chemotherapy
  • Prior ipsilateral breast cancer or thoracic radiation
  • Poor breast integrity
  • Paget's Disease of the nipple
  • Pregnant patients
  • Severe cardiac, pulmonary, or liver diseases

Treatment and study plan

Stereotactic Body Radiation Therapy

Radiation

Treatment technique used to deliver a highly focused and accurate radiation dose to a defined target volume outside the brain; the entire course of therapy delivered in five fractions or less

Primary outcomes

  1. Breast Cosmesis as measured by NRG-Radiation Therapy Oncology Group (RTOG) global cosmetic score (GCS) and the Harvard Cosmesis Scale (HCS)

    Time frame: 2-3 years

    physician and patient assessment of breast cosmetic result following SBRT

  2. Acute breast toxicity as measured by Common Terminology Criteria for Adverse Events (CTCAE) version 4.0

    Time frame: 1-6 weeks

    assessment of skin and breast tissue changes during and immediately following SBRT

  3. Other late toxicities as measured by Common Terminology Criteria for Adverse Events (CTCAE) version 4.0

    Time frame: 3-60 months

    assessment of pulmonary, cardiac and chest wall changes following SBRT

Study contacts

Contact information is provided by the study sponsor or research team.

Debra Freeman, MD

CONTACT

[email protected]

239-262-5168

Mark Perman, MD

CONTACT

[email protected]

772-293-0377

Sponsors and collaborators

Lead sponsor

RPCR, Inc.

Other

Collaborators

  • CyberKnife Coalition

Registry information

Official study title

Accelerated Partial Breast Irradiation (APBI) Using Stereotactic Body Radiation Therapy (SBRT): a Multicenter, Observational Clinical Trial

Important dates

Study start
2022
Primary completion
2024
Study completion
2027
First posted
Aug 2, 2021
Registry last updated
Aug 5, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.